Tumor-Targeted pan-RAS Inhibition as a Novel Biologic Therapy for Diffuse Midline Glioma

Stefanie-Grace Sbergio

doi:10.1093/neuonc/noag148

Tumor-Targeted pan-RAS Inhibition as a Novel Biologic Therapy for Diffuse Midline Glioma

2026-06-29

0

OA

AI

S

Stefanie-Grace Sbergio

H

Huazhu Liang

L

Lucy Chen

L

Laura Canty

S

Sheyenne Carette

S

Sanja Pajovic

N

Nesrin Sabha

A

Arun Kumaran Anguraj Vadivel

G

Greg L Beilhartz

R

Roman A Melnyk

C

Cynthia Hawkins *

DOI：10.1093/neuonc/noag148

Original

Original request for help

Save

Abstract

En 中文

Pediatric high-grade gliomas (pHGG) are the leading cause of childhood cancer–related deaths. Those arising in the midline harboring a lysine to methionine substitution at position 27 in histone 3 (H3K27M), termed diffuse midline glioma (or DIPG when occurring in the pons), are particularly deadly and in need of additional therapeutic options. Our group and others have found upregulation of the RAS/MAPK pathway across HGGs, including DIPG; however, RAS is notoriously difficult to target therapeutically, with no approved drugs that can target non-mutant RAS proteins.

Tumor-Targeted pan-RAS Inhibition as a Novel Biologic Therapy for Diffuse Midline Glioma

Abstract

Journal

Organization

Cited Papers

Citing Papers